Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)

Public Assistance-Hospitals of Marseille (AP-HM)

Status

Active, not recruiting

Conditions

Non-small Cell Lung Cancer Patients

Treatments

Procedure: BIOPSY

Diagnostic Test: blood-sampled

Other: feces samples

Study type

Interventional

Funder types

Other

Identifiers

NCT03493581

2017-67

2018-A03518-45 (Other Identifier)

Details and patient eligibility

About

PIONeeR study is a prospective, multicenter study without administration of an investigational product.

The promotion and funding will be done by the Assistance Publique Hôpitaux de Marseille (APHM), the coordination by AMU. There will be 3 principal investigational clinical centres in France:

Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques in APHM, Marseille, supervised by Prof. L. Greillier
Medical Oncology Department of Centre Léon Bérard, Lyon, supervised by Prof. M. Pérol
Unité d'Oncologie Thoracique, CHU Larrey /Oncopôle, Toulouse, supervised by Prof. J. Mazières.

Some secondary centres, nearby the three principal mentioned above, will be associated to ensure recruitment of patients, in accordance to provisional planning.

The primary objective is to validate the existence and distribution of the hypothetical immune profile (within blood and tumoral tissue) explaining primary or adaptive resistance to standard PD-1 inhibitors monotherapy, in NSCLC patients.
The secondary objectives are to better characterize :
- PK/PD relationships,
- inter-patient PK variability,
- If systemic exposure levels could be predictive of efficacy of PD-1 ICI, in NSCLC patients.
Some exploratory objectives are :
- to assess a predictive value of a panel of endothelial biomarkers, in NSCLC patients.
- to compare predictive immune & endothelial biomarker profiles with those of sensitive tumors.
- to better understand which profiles track significantly with progression following PD-1 ICI administration, in order to improve advanced NSCLC patients' stratification, for future clinical trials.

Full description

Visits will match with usual schedule of patient's appointments with their referent oncologist or for injections of ICIs, when blood sampling or biopsies will be done. Feces will be collected by patients themselves, at home (optional).

The same day of registration for either an EMA approved first line PD-1 or PD-L1 inhibitor in combination with platinum-based chemotherapy OR a standard 2nd or 3rd line PD-(L) 1 ICIs monotherapy (to date, Nivolumab, Pembrolizumab, Atezolizumab), 450 advanced NSCLC patients will undergo a screening visit (Vs). If they are eligible, after signing an informed written consent, they will be blood-sampled specifically for the study:

after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),
after 6 weeks (V2),
after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),
after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).
after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),
after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses).

Patients will also be re-biopsied (primitive tumor or metastasis) specifically for the study, at V2. Referent patients'oncologist will opt for the simplest technical approach with a minimal risk exposure for patients. Standard procedures will be implemented for subsequent patient's monitoring.

Patients will also provide remaining samples from pre-treatment surgical resections/biopsies (primitive tumor or metastasis).

If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).

Following the last study visit (V4 or V5 or V6)or at the time of a subsequent disease progression, patients will enter to the follow up period (a minimum 24 weeks ). They will be followed by their usual referent oncologist, no additional visit is required. Subsequent response to the anti-PD (L) 1 treatment, anti-cancer therapy, survival will be collected via patient medical records and analysed for current study.

Enrollment

450 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

- Patients must be over 18 years
Patients must have histologically confirmed diagnosis of advanced (proven stade IV) or recurrent NSCLC,
Their ECOG Performance Status must be of 0 or 1
EITHER patients must be previously untreated and eligible for an EMA approved first line PD-1 or PD-L1 inhibitor in combination with platinum-based chemotherapy, irrespective of their tumor histology
These EMA approved first line combinations must be reimbursed by French Health Insurance or at least, must have an Authorization for Temporary Use (ATU) in France
OR Patients must display disease progression after at least one line of platinum-based chemotherapy and eligible for a registered second or third line PD-1 or PD-L1 inhibitor in monotherapy (to date, Nivolumab, Pembrolizumab, Atezolizumab)
For patients registered for a 2nd or 3rd line, those with known actionable molecular alteration (EGFR activating mutation, ALK rearrangement, ROS1 rearrangement) should have received a specific inhibitor
Patients must have an available archived tissue from a standard tumor biopsy for PD-L1 assessment, done before PD-1 ICI initiation
Patients must have an available archived tissue from a standard tumor biopsy for PD-L1 assessment, done before PD-1 ICI initiation
Patients must have adequate organ functions
Patients must have provided a signed and dated, written informed consent prior to any study specific procedures, sampling and analyses

Exclusion criteria

Patients previously untreated and eligible for a first line PD-1 or PD-L1 inhibitor in monotherapy
Combination of PD-1 or PD-L1 inhibitor with bevacizumab
Exclusive bone progression
Exclusive cerebral progression not amenable to surgical biopsy
Absence of a target lesion according to RECIST criteria 1.1
Life expectancy of less than 3 months
Severe adverse events from PD-1 treatment
Abnormal coagulation contraindicating biopsy
History of hemorrhagic or thrombotic stroke, TIA or other CNS bleeds
Active uncontrolled or serious infection (viral, bacterial or fungal)
Active infection including VHB and VHC infections
Individuals deprived of liberty or placed under the authority of a tutor
Patient unable to understand, read and/or sign an informed consent
Any condition which in the Investigator's opinion would jeopardize compliance with the protocol of the study
Patients without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme
Pregnant or breast-feeding women